FTS Study in Patients With Advanced Hematologic Malignancies
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
Determining the maximum tolerated dose (MTD) and pharmacokinetics (PK) of FTS (S-Trans,
Trans-Farnesylthiosalicylic Acid) after daily oral administration on Days 1 through 21 of a
28-Day cycle to patients with advanced hematologic malignancies that have progressed
following effective therapy or for which no effective therapy exists.